EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The promise of GLP-1 receptor agonists for neurodegenerative diseases

Dilan Athauda, Nigel H Greig, Wassilios G Meissner, Thomas Foltynie, Sonia Gandhi

Journal of Clinical Investigation · 16.02.2026 · 136 (4)

DOI: 10.1172/jci194745 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.02.2026. Verfasst von Dilan Athauda und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Francis Crick Institute, London, United Kingdom. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Neurodegenerative Diseases, Neuroprotective Agents. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 243 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), established therapies for type 2 diabetes and obesity, are increasingly recognized for their potential in neurodegenerative diseases. Preclinical studies across diverse neurodegenerative conditions consistently demonstrate neuroprotective effects of GLP-1RAs, including reduced protein aggregation, enhanced autophagy, improved mitochondrial function, suppression of neuroinflammation, and preservation of synaptic integrity. Epidemiological analyses further suggest reduced incidence of dementia, Parkinson disease, and multiple sclerosis among long-term GLP-1RA users. Early human trials provide signals of target engagement, such as preserved cerebral glucose metabolism, altered inflammatory biomarkers, and slowed brain atrophy, although clinical outcomes to date remain mixed and trials in rarer disorders are sparse. Translation is constrained by uncertainty around optimal molecule choice, CNS penetrance, tolerability, adherence, and heterogeneity of response. Furthermore, next-generation dual and triple agonists may offer enhanced efficacy but remain untested in neurodegeneration. Conceptually, GLP-1RAs share pleiotropic effects with exercise — one of the few interventions with proven disease-modifying potential — by enhancing insulin signaling, stabilizing mitochondria, reducing inflammation, and promoting synaptic plasticity. This overlap highlights their promise as “pharmacological analogues of exercise,” and underscores the need for biomarker-driven, disease-specific trials to establish whether GLP-1RAs can deliver durable disease modification across the spectrum of neurodegenerative diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsNeurodegenerative DiseasesNeuroprotective AgentsHumansAnimalsGlucagon-Like Peptide-1 ReceptorMitochondria

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorNeuroprotective Agents

Autor:innen und Institutionen

  • The Francis Crick Institute, London, United Kingdom.
  • Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.
  • Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, NIH, Baltimore, Maryland, USA.
  • CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, IMNc, Bordeaux, France.
  • University de Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, France.
  • Department of Medicine, University of Otago, Christchurch, and New Zealand Brain Research Institute, Christchurch, New Zealand.

Zitieren

APA

Athauda, D., Greig, N. H., Meissner, W. G., Foltynie, T., & Gandhi, S. (2026). The promise of GLP-1 receptor agonists for neurodegenerative diseases. Journal of Clinical Investigation, 136(4). https://doi.org/10.1172/jci194745

Vancouver

Athauda D, Greig NH, Meissner WG, Foltynie T, Gandhi S. The promise of GLP-1 receptor agonists for neurodegenerative diseases. Journal of Clinical Investigation. 2026;136(4). doi:10.1172/jci194745

BibTeX
@article{Athauda2026,
  author = {Athauda, Dilan and Greig, Nigel H and Meissner, Wassilios G and Foltynie, Thomas and Gandhi, Sonia},
  title = {The promise of GLP-1 receptor agonists for neurodegenerative diseases},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {4},
  doi = {10.1172/jci194745}
}
Kostenlos starten →